Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.67T
- Enterprise value
- $1.67T
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $18.99
- 52-wk low
- $0.12
- Beta
- —
- Shares out
- 91.57B
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Overview We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. PH1’s disruption of normal RNA splicing has multiple modes of action on cancer cells: 1) cell killing and cytotoxicity that causes cancer cell death and 2) generates neoantigen proteins that activates both the innate and adaptive immune systems to drive robust and durable cancer…
AI summary unavailable — showing raw filing excerpt
Generated from AKTX's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors. Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below in addition to the other information included or incorporated by reference in this Form 10-K before purchasing our ADSs. Our business, financial condition and results of operations could be materially and adversely affected by any of these and currently unknown risks or uncertainties. In that case, the market price of our ADSs could decline, and you may lose all or part of your investment in our securities. Risks Related to Our Financial Position and Our Capital Requirements We have a history of operating losses and cannot give…
AI summary unavailable — showing raw filing excerpt
Generated from AKTX's filing dated 2026-03-30
Profitability
Return on equity
-61.1%
31.4%Return on assets
-36.1%
7.7%Leverage
Debt / equity
0.69×
45.8%Debt / assets
40.9%
27.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-14.5M | -290.1% | — |
Q4 2025 2025-12-31 | — | — | $-5.3M | -40.5% | — |
Q3 2025 2025-09-30 | — | — | $-6.4M | -121.1% | — |
Q2 2025 2025-06-30 | — | — | $-1.9M | +74.9% | — |
Q1 2025 2025-03-31 | — | — | $-3.7M | +33.4% | — |
Q4 2024 2024-12-31 | — | — | $-3.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-2.9M | -0.8% | — |
Q2 2024 2024-06-30 | — | — | $-7.6M | -152.0% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AKTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$3.0M
Insider selling
$0
Net activity
+$3.0M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AKTX
Institutional value
$877
Total shares held
7.3K
Distinct holders
1
-20 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | IFP Advisors, Inc | 7.3K | $877 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AKTX's latest filing finishes processing.